President Joe Biden has recently frozen a rule signed by former President Donald Trump in December to lower the prices for prescription drugs such as insulin and epinephrine.
On Thursday, Biden’s Department of Health and Human Services (HHS) announced that the rule would be put on hold, along with several of Trump’s other rules pending a 60-day review.
On Wednesday, Biden’s Chief of Staff Ron Klain directed federal agencies to pause orders that are not yet effective, although the previous administration had signed and published them.
“This freeze is part of the Biden administration’s large-scale effort announced this week that will scrutinize the Trump administration’s health policies,” reported Bloomberg Law. “If the previous administration’s policies raise ‘fact, law, or policy’ concerns, the Biden HHS will delay them and consult with the Office of Management and Budget about other actions.”
In December, Trump had ordered community health centers that offer savings and discounts to low-income patients to purchase insulin and epinephrine in bulk to make high drug costs more affordable. However, the new administration has delayed the rule’s implementation until March 22, as it awaits their approval.
The Biden administration’s first days in office have so far been filled with sweeping executive orders signed by former President Trump.